BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodríguez-Perálvarez M, Mantzoukis K, O’Brien J, Thalassinos E, Papastergiou V. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess. 2015;19:1-409, v-vi. [PMID: 25633908 DOI: 10.3310/hta19090] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Armstrong MJ, Marchesini G. Referral pathways for NAFLD fibrosis in primary care - No longer a 'needle in a haystack'. J Hepatol 2019;71:246-8. [PMID: 31229270 DOI: 10.1016/j.jhep.2019.05.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Yoo J, Lee JM, Joo I, Lee DH, Yoon JH, Kang HJ, Ahn SJ. Reproducibility of ultrasound attenuation imaging for the noninvasive evaluation of hepatic steatosis. Ultrasonography 2020;39:121-9. [PMID: 31693842 DOI: 10.14366/usg.19034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
3 Wu R, Dong S, Cai FF, Chen XL, Yang MD, Liu P, Su SB. Active Compounds Derived from Fuzheng Huayu Formula Protect Hepatic Parenchymal Cells from Apoptosis Based on Network Pharmacology and Transcriptomic Analysis. Molecules 2019;24:E338. [PMID: 30669350 DOI: 10.3390/molecules24020338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Hussain A, Gul MA, Khalid MU. Validation of Novel Fibrosis Index (NFI) for assessment of liver fibrosis: comparison with transient elastography (FibroScan). BMJ Open Gastroenterol 2019;6:e000316. [PMID: 31749977 DOI: 10.1136/bmjgast-2019-000316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Morgan A, Hartmanis S, Tsochatzis E, Newsome PN, Ryder SD, Elliott R, Floros L, Hall R, Higgins V, Stanley G, Cure S, Vasudevan S, Pezzullo L. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. Eur J Health Econ 2021;22:505-18. [PMID: 33751289 DOI: 10.1007/s10198-020-01256-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wong RJ, Kachru N, Martinez DJ, Moynihan M, Ozbay AB, Gordon SC. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases. J Clin Gastroenterol 2021;55:891-902. [PMID: 32815873 DOI: 10.1097/MCG.0000000000001409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Grgurevic I, Podrug K, Mikolasevic I, Kukla M, Madir A, Tsochatzis EA. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Can J Gastroenterol Hepatol 2020;2020:9181368. [PMID: 32051820 DOI: 10.1155/2020/9181368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
8 Ishida K, Namisaki T, Murata K, Fujimoto Y, Takeda S, Enomoto M, Ogawa H, Takagi H, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Sawada Y, Kitagawa K, Sato S, Nishimura N, Takaya H, Kaji K, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. J Clin Med 2020;9:E3510. [PMID: 33138335 DOI: 10.3390/jcm9113510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Besutti G, Valenti L, Ligabue G, Bassi MC, Pattacini P, Guaraldi G, Giorgi Rossi P. Accuracy of imaging methods for steatohepatitis diagnosis in non‐alcoholic fatty liver disease patients: A systematic review. Liver Int 2019;39:1521-34. [DOI: 10.1111/liv.14118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
10 Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol 2018;3:509-17. [PMID: 29893235 DOI: 10.1016/S2468-1253(18)30077-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 22] [Article Influence: 16.7] [Reference Citation Analysis]
11 Wong RJ, Liu B, Bhuket T. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2017;46:974-980. [PMID: 28914448 DOI: 10.1111/apt.14327] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
12 Shinkins B, Yang Y, Abel L, Fanshawe TR. Evidence synthesis to inform model-based cost-effectiveness evaluations of diagnostic tests: a methodological review of health technology assessments. BMC Med Res Methodol 2017;17:56. [PMID: 28410588 DOI: 10.1186/s12874-017-0331-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 Orasan OH, Iancu M, Sava M, Saplontai-Pop A, Cozma A, Sarlea ST, Lungoci C, Ungureanu MI, Negrean V, Sampelean D, Dumitrascu DL. Non-invasive assessment of liver fibrosis in chronic viral hepatitis. Eur J Clin Invest 2015;45:1243-51. [PMID: 26426402 DOI: 10.1111/eci.12543] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
14 Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017;5:40. [PMID: 28251119 DOI: 10.21037/atm.2017.01.28] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
15 Petta S, Ting J, Saragoni S, Degli Esposti L, Shreay S, Petroni ML, Marchesini G. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. Nutrition, Metabolism and Cardiovascular Diseases 2020;30:1014-22. [DOI: 10.1016/j.numecd.2020.02.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, Mccabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, Mckane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D. Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants Appl Res 2018;6:1-528. [DOI: 10.3310/pgfar06030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Johansen P, Howard D, Bishop R, Moreno SI, Buchholtz K. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. Pharmacoeconomics 2020;38:485-97. [PMID: 31919793 DOI: 10.1007/s40273-019-00881-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Njei B, McCarty TR, Luk J, Ewelukwa O, Ditah I, Lim JK. Use of transient elastography in patients with HIV-HCV coinfection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2016;31:1684-93. [PMID: 26952020 DOI: 10.1111/jgh.13337] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
19 Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl) 2018;8:21-9. [PMID: 29785393 DOI: 10.2147/PTT.S141629] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
20 Bugianesi E. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action? Diabetologia 2016;59:1145-7. [DOI: 10.1007/s00125-016-3930-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
21 Lombardi R, Lever R, Smith C, Marshall N, Rodger A, Bhagani S, Tsochatzis E. Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers. Ann Gastroenterol 2017;30:349-56. [PMID: 28469366 DOI: 10.20524/aog.2017.0141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
22 Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, Tsochatzis E, de Ledinghen V, Bugianesi E, Romero-Gomez M, Bantel H, Ryder SD, Boursier J, Leroy V, Crespo J, Castera L, Floros L, Atella V, Mestre-Ferrandiz J, Elliott R, Kautz A, Morgan A, Hartmanis S, Vasudevan S, Pezzullo L, Trylesinski A, Cure S, Higgins V, Ratziu V. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int 2021;41:1227-42. [PMID: 33590598 DOI: 10.1111/liv.14825] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
23 Roccarina D, Rosselli M, Genesca J, Tsochatzis EA. Elastography methods for the non-invasive assessment of portal hypertension. Expert Rev Gastroenterol Hepatol 2018;12:155-64. [PMID: 28856972 DOI: 10.1080/17474124.2017.1374852] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 6.2] [Reference Citation Analysis]
24 Moura Cunha G, Navin PJ, Fowler KJ, Venkatesh SK, Ehman RL, Sirlin CB. Quantitative magnetic resonance imaging for chronic liver disease. Br J Radiol 2021;94:20201377. [PMID: 33635729 DOI: 10.1259/bjr.20201377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Dong S, Cai FF, Chen QL, Song YN, Sun Y, Wei B, Li XY, Hu YY, Liu P, Su SB. Chinese herbal formula Fuzheng Huayu alleviates CCl4-induced liver fibrosis in rats: a transcriptomic and proteomic analysis. Acta Pharmacol Sin 2018;39:930-41. [PMID: 29094729 DOI: 10.1038/aps.2017.150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
26 Fujii H, Enomoto M, Fukumoto S, Kimura T, Nadatani Y, Takashima S, Hagihara A, Uchida-Kobayashi S, Tamori A, Nishimoto N, Kawada N. Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis. JGH Open 2021;5:801-8. [PMID: 34263075 DOI: 10.1002/jgh3.12590] [Reference Citation Analysis]
27 Newsum AM, Kooij KW, Boyd A, Smit C, Wit FWNM, van der Meer JTM, Prins M, Reiss P, van der Valk M; MOSAIC study group, ATHENA observational HIV cohort and NVHB-SHM hepatitis working group. Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM. AIDS 2019;33:833-44. [PMID: 30649050 DOI: 10.1097/QAD.0000000000002138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lambrecht J, Verhulst S, Mannaerts I, Reynaert H, van Grunsven LA. Prospects in non-invasive assessment of liver fibrosis: Liquid biopsy as the future gold standard? Biochim Biophys Acta Mol Basis Dis. 2018;1864:1024-1036. [PMID: 29329986 DOI: 10.1016/j.bbadis.2018.01.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
29 Subic M, Zoulim F. How to improve access to therapy in hepatitis B patients. Liver Int 2018;38 Suppl 1:115-21. [PMID: 29427482 DOI: 10.1111/liv.13640] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
30 Srivastava A, Jong S, Gola A, Gailer R, Morgan S, Sennett K, Tanwar S, Pizzo E, O'Beirne J, Tsochatzis E, Parkes J, Rosenberg W. Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterol 2019;19:122. [PMID: 31296161 DOI: 10.1186/s12876-019-1039-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
31 Lombardi R, Sambatakou H, Mariolis I, Cokkinos D, Papatheodoridis GV, Tsochatzis EA. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Dig Liver Dis. 2016;48:1471-1477. [PMID: 27623186 DOI: 10.1016/j.dld.2016.08.117] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
32 Abe H, Midorikawa Y, Okada M, Takayama T. Clinical application of magnetic resonance elastography in chronic liver disease: Performance of MRE in CLD. Hepatol Res 2018;48:780-7. [DOI: 10.1111/hepr.13231] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
33 Martin NK, Vickerman P, Khakoo S, Ghosh A, Ramsay M, Hickman M, Williams J, Miners A. Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. BMJ Open 2019;9:e030183. [PMID: 31256040 DOI: 10.1136/bmjopen-2019-030183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
34 Jabor A, Kubíček Z, Fraňková S, Šenkeříková R, Franeková J. Enhanced liver fibrosis (ELF) score: Reference ranges, biological variation in healthy subjects, and analytical considerations. Clinica Chimica Acta 2018;483:291-5. [DOI: 10.1016/j.cca.2018.05.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Majumdar A, Campos S, Gurusamy K, Pinzani M, Tsochatzis EA. Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study. Hepatology 2020;71:627-42. [PMID: 31297832 DOI: 10.1002/hep.30846] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
36 Sharma C, Cococcia S, Ellis N, Parkes J, Rosenberg W. Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. J Gastroenterol Hepatol 2021;36:1788-802. [PMID: 33668077 DOI: 10.1111/jgh.15482] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Crossan C, Majumdar A, Srivastava A, Thorburn D, Rosenberg W, Pinzani M, Longworth L, Tsochatzis EA. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. Liver Int. 2019;39:2052-2060. [PMID: 31332938 DOI: 10.1111/liv.14198] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
38 Roccarina D, Iogna Prat L, Buzzetti E, Guerrero Misas M, Aricó FM, Saffioti F, Rosselli M, Pinzani M, Marshall A, Thorburn D, Tsochatzis E. Establishing Reliability Criteria for Liver ElastPQ Shear Wave Elastography (ElastPQ-SWE): Comparison Between 10, 5 and 3 Measurements. Ultraschall Med 2021;42:204-13. [PMID: 31594008 DOI: 10.1055/a-1010-6052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Soto M, Sampietro-Colom L, Lasalvia L, Mira A, Jiménez W, Navasa M. Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. World J Gastroenterol 2017; 23(17): 3163-3173 [PMID: 28533673 DOI: 10.3748/wjg.v23.i17.3163] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
40 Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol 2015;2015:343828. [PMID: 26064107 DOI: 10.1155/2015/343828] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
41 Staufer K, Dengler M, Huber H, Marculescu R, Stauber R, Lackner C, Dienes HP, Kivaranovic D, Schachner C, Zeitlinger M, Wulkersdorfer B, Rauch P, Prager G, Trauner M, Mikulits W. The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death Dis. 2017;8:e3135. [PMID: 29072690 DOI: 10.1038/cddis.2017.554] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
42 Xu XY, Wang WS, Zhang QM, Li JL, Sun JB, Qin TT, Liu HB. Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. World J Clin Cases 2019; 7(15): 2022-2037 [PMID: 31423434 DOI: 10.12998/wjcc.v7.i15.2022] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
43 Rowe IA. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 2018;3:66-72. [PMID: 29254617 DOI: 10.1016/S2468-1253(17)30142-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
44 Friedrich-rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol 2016;13:402-11. [DOI: 10.1038/nrgastro.2016.86] [Cited by in Crossref: 127] [Cited by in F6Publishing: 102] [Article Influence: 21.2] [Reference Citation Analysis]
45 Doyle JS, Aspinall EJ, Hutchinson SJ, Quinn B, Gore C, Wiktor SZ, Hellard ME. Global policy and access to new hepatitis C therapies for people who inject drugs. International Journal of Drug Policy 2015;26:1064-71. [DOI: 10.1016/j.drugpo.2015.05.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
46 Potts J, Maybury C, Salam A, Barker J, Agarwal K, Smith C. Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. Br J Dermatol 2017;177:637-44. [DOI: 10.1111/bjd.15246] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Lemmer A, VanWagner LB, Ganger D. Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy. Hepatology. 2018;68:1633-1641. [PMID: 29672883 DOI: 10.1002/hep.30048] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
48 Feng Y, Ying HY, Qu Y, Cai XB, Xu MY, Lu LG. Novel matrine derivative MD-1 attenuates hepatic fibrosis by inhibiting EGFR activation of hepatic stellate cells. Protein Cell 2016;7:662-72. [PMID: 27342773 DOI: 10.1007/s13238-016-0285-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
49 Papatheodoridi M, Pinzani M, Tsochatzis E. Reply to: "Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD" and "Transient elastography in chronic liver disease: Beware of the cut-offs!". J Hepatol 2021;75:1247. [PMID: 34453965 DOI: 10.1016/j.jhep.2021.07.036] [Reference Citation Analysis]
50 Hessin AF, Hegazy RR, Hassan AA, Yassin NZ, Kenawy SA. Resveratrol prevents liver fibrosis via two possible pathways: Modulation of alpha fetoprotein transcriptional levels and normalization of protein kinase C responses. Indian J Pharmacol 2017;49:282-9. [PMID: 29326488 DOI: 10.4103/ijp.IJP_299_16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. JHEP Rep 2021;3:100219. [PMID: 33659890 DOI: 10.1016/j.jhepr.2020.100219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Castro R, Crathorne L, Perazzo H, Silva J, Cooper C, Varley-Campbell J, Marinho DS, Haasova M, Veloso VG, Anderson R, Hyde C. Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Med Res Methodol 2018;18:53. [PMID: 29895281 DOI: 10.1186/s12874-018-0515-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
53 Mendonça da Silva J, Stamatis C, Chalmers SA, Erro E, Selden C, Farid SS. Decisional tool for cost of goods analysis of bioartificial liver devices for routine clinical use. Cytotherapy 2021;23:683-93. [PMID: 34116945 DOI: 10.1016/j.jcyt.2021.04.006] [Reference Citation Analysis]
54 Morling JR, Guha IN. Biomarkers of liver fibrosis. Clin Liver Dis (Hoboken) 2016;7:139-42. [PMID: 31041049 DOI: 10.1002/cld.555] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
55 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
56 Cook N, Geier A, Schmid A, Hirschfield G, Kautz A, Schattenberg JM, Balp MM. The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs. Front Med (Lausanne) 2019;6:61. [PMID: 31106203 DOI: 10.3389/fmed.2019.00061] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
57 Lombardi R, Buzzetti E, Roccarina D, Tsochatzis EA. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. World J Gastroenterol 2015; 21(39): 11044-11052 [PMID: 26494961 DOI: 10.3748/wjg.v21.i39.11044] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
58 Buzzetti E, Hall A, Ekstedt M, Manuguerra R, Guerrero Misas M, Covelli C, Leandro G, Luong T, Kechagias S, Manesis EK, Pinzani M, Dhillon AP, Tsochatzis EA. Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;49:1214-22. [PMID: 30882933 DOI: 10.1111/apt.15219] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
59 Tsochatzis EA, Srivastava A, Rosenberg W. Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease". J Hepatol 2020;73:217-8. [PMID: 32265051 DOI: 10.1016/j.jhep.2020.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Blake L, Duarte RV, Cummins C. Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging. BMJ Open 2016;6:e010507. [PMID: 27650757 DOI: 10.1136/bmjopen-2015-010507] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
61 Prinja S, Jyani G, Bahuguna P, Faujdar DS, Kumar R. Reply to When flawed modeling justifies cost-effectiveness: Making sense of "Band-Aid" modeling. Cancer 2018;124:3267-70. [PMID: 29750834 DOI: 10.1002/cncr.31544] [Reference Citation Analysis]
62 Thiele M, Kjaergaard M, Thielsen P, Krag A. Contemporary use of elastography in liver fibrosis and portal hypertension. Clin Physiol Funct Imaging. 2017;37:235-242. [PMID: 26459184 DOI: 10.1111/cpf.12297] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
63 Al Khayat MNMT, Eijsink JFH, Postma MJ, Wilschut JC, van Hulst M. The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands. Int J Environ Res Public Health 2020;17:E6091. [PMID: 32825680 DOI: 10.3390/ijerph17176091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 van Katwyk S, Coyle D, Cooper C, Pussegoda K, Cameron C, Skidmore B, Brener S, Moher D, Thavorn K. Transient elastography for the diagnosis of liver fibrosis: a systematic review of economic evaluations. Liver Int. 2016;37:851-861. [PMID: 27699993 DOI: 10.1111/liv.13260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
65 Méndez-Sánchez N, Qi X, Vitek L, Arrese M. Evaluating an Outpatient With an Elevated Bilirubin. Am J Gastroenterol 2019;114:1185-8. [PMID: 31318706 DOI: 10.14309/ajg.0000000000000336] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. Gastroenterology 2017;152:1544-77. [PMID: 28442120 DOI: 10.1053/j.gastro.2017.03.016] [Cited by in Crossref: 135] [Cited by in F6Publishing: 137] [Article Influence: 27.0] [Reference Citation Analysis]
67 Tsochatzis EA, Castera L. Assessing liver disease in HIV–HCV coinfected patients: . Current Opinion in HIV and AIDS 2015;10:316-22. [DOI: 10.1097/coh.0000000000000176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
68 Asphaug L, Thiele M, Krag A, Melberg HO. Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis.Hepatology. 2020;71:2093-2104. [PMID: 31595545 DOI: 10.1002/hep.30979] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
69 Liaqat M, Siddique K, Yousaf I, Bacha R, Farooq SMY, Gilani SA. Comparison between shear wave elastography and serological findings for the evaluation of fibrosis in chronic liver disease. J Ultrason 2021;21:e186-93. [PMID: 34540271 DOI: 10.15557/JoU.2021.0030] [Reference Citation Analysis]
70 Zakeri N, Tsochatzis EA. Steatosis affects the sensitivity but not the specificity of non-invasive fibrosis tests in non-alcoholic fatty liver disease - implications for screening strategies. Liver Int 2018;38:224-6. [DOI: 10.1111/liv.13602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 Jafarov F, Kaya E, Bakir A, Eren F, Yilmaz Y. The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. Eur J Gastroenterol Hepatol 2020;32:642-9. [PMID: 31651653 DOI: 10.1097/MEG.0000000000001573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
72 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
73 Papatheodoridi M, Hiriart JB, Lupsor-Platon M, Bronte F, Boursier J, Elshaarawy O, Marra F, Thiele M, Markakis G, Payance A, Brodkin E, Castera L, Papatheodoridis G, Krag A, Arena U, Mueller S, Cales P, Calvaruso V, de Ledinghen V, Pinzani M, Tsochatzis EA. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol 2021;74:1109-16. [PMID: 33307138 DOI: 10.1016/j.jhep.2020.11.050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
74 Hydes T, Gilmore W, Sheron N, Gilmore I. Treating alcohol-related liver disease from a public health perspective. J Hepatol. 2019;70:223-236. [PMID: 30658724 DOI: 10.1016/j.jhep.2018.10.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
75 Cerier E, Beal EW, Chakedis J, Chen Q, Paredes A, Sun S, Cloyd JM, Pawlik TM. Patient-provider relationships and health outcomes among hepatopancreatobiliary patients. Journal of Surgical Research 2018;228:290-8. [DOI: 10.1016/j.jss.2018.03.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
76 Cipriano LE, Goldhaber-Fiebert JD. Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy Pract 2018;3:2381468318776634. [PMID: 30288448 DOI: 10.1177/2381468318776634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
77 Povsic M, Wong OY, Perry R, Bottomley J. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). Adv Ther 2019;36:1574-94. [PMID: 31065991 DOI: 10.1007/s12325-019-00960-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
78 Singh J, Longworth L. COMPARISON OF METHODS FOR ESTIMATING CONTEMPORARY COSTS: AN APPLICATION TO LIVER TRANSPLANTATION IN THE UNITED KINGDOM. Int J Technol Assess Health Care 2017;33:620-8. [PMID: 28934994 DOI: 10.1017/S026646231700071X] [Reference Citation Analysis]
79 Iogna Prat L, Roccarina D, Lever R, Lombardi R, Rodger A, Hall A, Luong TV, Bhagani S, Tsochatzis EA. Etiology and Severity of Liver Disease in HIV-Positive Patients With Suspected NAFLD: Lessons From a Cohort With Available Liver Biopsies. J Acquir Immune Defic Syndr 2019;80:474-80. [PMID: 30807482 DOI: 10.1097/QAI.0000000000001942] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
80 Tsochatzis EA, Srivastava A, Rosenberg W. Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)". J Hepatol 2021;74:248-9. [PMID: 32981752 DOI: 10.1016/j.jhep.2020.09.007] [Reference Citation Analysis]
81 Issa F, Strober S, Leventhal JR, Kawai T, Kaufman DB, Levitsky J, Sykes M, Mas V, Wood KJ, Bridges N, Welniak LA, Chandran S, Madsen JC, Nickerson P, Demetris AJ, Lakkis FG, Thomson AW. The Fourth International Workshop on Clinical Transplant Tolerance. Am J Transplant 2021;21:21-31. [PMID: 32529725 DOI: 10.1111/ajt.16139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
82 Mallet V, Parlati L, Vallet-Pichard A, Terris B, Tsochatzis E, Sogni P, Pol S. [FIB-4 index to rule-out advanced liver fibrosis in NAFLD patients]. Presse Med 2019;48:1484-8. [PMID: 31767251 DOI: 10.1016/j.lpm.2019.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
83 Stasi C, Tsochatzis EA, Hall A, Rosenberg W, Milani S, Dhillon AP, Pinzani M. Comparison and correlation of fibrosis stage assessment by collagen proportionate area (CPA) and the ELF panel in patients with chronic liver disease. Dig Liver Dis 2019;51:1001-7. [PMID: 30606698 DOI: 10.1016/j.dld.2018.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
84 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Papastergiou V, Thalassinos E, Mantzoukis K, Rodriguez-Peralvarez M, O'Brien J, Noel-Storr A, Papatheodoridis GV, Davidson B, Burroughs AK. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation. J Viral Hepat 2016;23:139-49. [PMID: 26444996 DOI: 10.1111/jvh.12469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]